Table 2 Post-transplant patient characteristics.

From: Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis

Characteristics

PtCy

 

MRD

 

MUD

 

MM

 

p value

n

68

 

97

 

280

 

54

  

GvHD, n (%)

PtCy

 

MRD

 

MUD

 

MM

  

aGvHD > I n (%)

26

38%

52

54%

80

29%

21

39%

<0.001b

cGvHD moderate or severe (%)

16

24%

51

53%

45

16%

9

17%

<0.001b

Immunosuppressive therapies

PtCy

 

MRD

 

MUD

 

MM

  

Patient with systemic Steroids, n (%)

41

60%

78

80%

133

48%

31

57%

<0.001b

Patient with Ruxolitinib, n (%)

14

21%

41

42%

41

15%

12

22%

<0.001b

Death, n (%)

PtCy

 

MRD

 

MUD

 

MM

  

Overall deceased, n (%)

28

41%

42

43%

88

31%

32

59%

<0.001b

Median duration till fatal event (days)

88

 

197

 

258

 

229

 

<0.05a

Death due to Relapse, n (%)

9

13%

24

25%

44

16%

13

24%

>0.05b

Death due to infection, n (%)

11

16%

10

10%

25

9%

12

22%

<0.05b

Death due to GvHD, n (%)

3

4%

3

3%

7

3%

3

6%

>0.05b

EBV and CMV reactivations, n (%)

PtCy

 

MRD

 

MUD

 

MM

  

CMV reactivation incidence (R+)

17

43%

24

47%

76

49%

28

82%

<0.01b

EBV reactivation incidence

4

6%

3

3%

27

10%

9

17%

<0.05b

  1. aFor median duration till fatal event (days) as a continuous variable, a Kruskal–Wallis test was used. Post hoc analysis can be found in Fig. 5.
  2. bAll other variables are categorical; thus, a chi-square test was used to assess significance for event occurrence
Back to article page